VYNE Therapeutics (VYNE) to Release Earnings on Thursday

VYNE Therapeutics (NASDAQ:VYNE) will likely be posting its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect VYNE Therapeutics to post earnings of ($0.19) per share for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Monday, November 10, 2025 at 12:30 PM ET.

VYNE Therapeutics (NASDAQ:VYNE) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.10. VYNE Therapeutics had a negative return on equity of 77.57% and a negative net margin of 8,097.69%.The business had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.15 million. On average, analysts expect VYNE Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

VYNE Therapeutics Stock Down 1.6%

VYNE opened at $0.35 on Thursday. VYNE Therapeutics has a 52 week low of $0.28 and a 52 week high of $4.30. The business has a fifty day simple moving average of $0.34 and a 200-day simple moving average of $0.85. The firm has a market cap of $8.83 million, a P/E ratio of -0.39 and a beta of 1.91.

Institutional Trading of VYNE Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in VYNE. Jane Street Group LLC acquired a new stake in shares of VYNE Therapeutics during the second quarter worth about $206,000. Adage Capital Partners GP L.L.C. increased its position in shares of VYNE Therapeutics by 87.2% during the second quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock worth $1,063,000 after purchasing an additional 300,000 shares in the last quarter. Finally, Boothbay Fund Management LLC acquired a new stake in shares of VYNE Therapeutics during the second quarter worth about $176,000. Institutional investors and hedge funds own 83.78% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on VYNE shares. HC Wainwright cut VYNE Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, July 30th. Weiss Ratings restated a “sell (e+)” rating on shares of VYNE Therapeutics in a research note on Wednesday, October 8th. Lifesci Capital cut VYNE Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 30th. Finally, BTIG Research cut VYNE Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, July 31st. Three investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, VYNE Therapeutics has an average rating of “Reduce” and an average target price of $6.25.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.